Biome Diagnostics, previously known as myBioma, has been mentioned as number 51 in the Top 100 best Start-Ups in Austria according to the Ranking from the magazine Trend! (https://www.trend.at/trendventure/oesterreichs-beste-start-ups)
Every year the magazine Trend nominates the Top 100 Start-Ups in Austria. Biome Diagnostics is for second time listed! This is motivating for the entire team and inspires to keep innovating and producing new cutting-edge microbiome-based technologies!
BiomeOne describes the current efforts of BiomeDx towards the world’s first stool-based response prediction test for immunotherapy (ICI). Currently, the biomarker is tested in three tumor types: non-small-cell lung cancer, renal cell carcinoma and malignant melanoma. Early research efforts support the idea of a tumor agnostic biomarker that can be used for any tumor type.
Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.
